TR1801-ADC in Patients With Tumors That Express c-Met

ClinicalTrials.gov ID: NCT03859752

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03859752. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of TR1801-ADC in patients with select solid tumors that express c-Met.

Study identification

NCT ID: NCT03859752
Recruitment status: Suspended
Study type: Interventional
Phase: Phase 1
Lead sponsor: Open Innovation Partners, Inc.; Industry
Enrollment: 15 participants

Conditions and interventions

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

TR1801-ADC Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 14, 2019 (Actual)
Primary completion: Jul 4, 2023 (Actual)
Completion: Dec 31, 2023 (Estimated)
Last update posted: Sep 22, 2023

2019 – 2023

United States locations

U.S. sites: 4
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
University of Southern California Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
University of Colorado	Aurora	Colorado	80045	—
John Hopkins - Sidney Kimmel Comprehensive Cancer Center	Baltimore	Maryland	21287	—
University of Washington / Seattle Cancer Care	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03859752, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 22, 2023 · Synced Nov 13, 2026